Overview

Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
To determine the number of men who have suppression of sperm production when using a daily regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel applied transdermally.
Phase:
Phase 1
Details
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Health Decisions
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Population Council
Treatments:
Methyltestosterone
ST 1435
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate